Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001

被引：5
|
作者：
Treiber, G. [1 ]
机构：
[1] Zollemalb Clin, Dept Internal Med, Balingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.
    Gilcrease, Glynn Weldon
    Weis, John R.
    Jones, Kimberly
    Davis, Thaylon
    Mitchell, Marlene
    Davidson, Cynthia
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [22] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Milowsky, M. I.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I.
    Flaherty, A.
    Tickoo, S.
    Al-Ahmadie, H.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
    Chen, Yajin
    Du, Chengyou
    Shen, Shunli
    Zhang, Wu
    Shan, Yunfeng
    Lyu, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Wang, Shutong
    Wang, Ting
    Dai, Shengjie
    Zhang, Shuhao
    Xie, Bingying
    Wu, Yinghao
    Hao, Chunyi
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2937 - 2944
  • [24] <bold>A single arm phase Ib study of RAD001 and sunitinib in </bold>patients with advanced renal cell carcinoma (RCC).
    Turnbull, J. D.
    Armstrong, A. J.
    Morris, K.
    Wood, S. E. Yenser
    Voyles, S.
    Fesko, Y. A.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report
    Hsu, C.
    Kang, Y.
    Yang, T.
    Su, W.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Button, P.
    Hsu, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study
    Zhang, Pei
    Li, Xiaofen
    Wang, Xin
    Yang, Yu
    Wang, Jianfei
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study
    Mu, Maoyuan
    Fu, Xiaobo
    Qi, Han
    Jiang, Weiwei
    Chen, Zixiong
    Gao, Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802
    Asano, M.
    Tanaka, S.
    Sato, A.
    Nakayama, N.
    Shimada, K.
    Konishi, K.
    Hibi, K.
    Sasaki, E.
    Kurihara, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).
    Ferrarotto, Renata
    Mata, Javier
    Mott, Frank
    Bhosale, Priya
    Rubin, M. Laura
    Altan, Mehmet
    Dervin, Shannon
    Yun, Cindy
    Yao, James C.
    Halperin, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
12345